Interestingly, patients with acute myeloid leukemia (AML) who undergo hematopoietic stem cell transplantation (HSCT) have a lower relapse rate and superior disease-free survival (DFS) when the donor and/or recipient is HCMV seropositive before transplantation; these individuals benefit from the expansion of CD56dimCD57+NKG2C+ adaptive NK cells in response to HCMV reactivation (87). Here, KLRC2 is linked to acute myeloid leukemia.